The disclosure relates to adamantyl-diamide derivatives of formula (I): wherein the variables R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt thereof； and pharmaceutical compositions and methods using the same. These compounds are suitable for the treatment of central nervous system disease or disorder selected from a cognitive, neurodegenerative, psychiatric or neurological disease or disorder, wherein the cognitive or neurodegenerative disease or disorder is selected from a group consisting of a mood disorder, an anxiety, a schizophrenia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's neurodegeneration, AIDS-induced encephalopathy, a non-AIDS-induced encephalopathy, Fragile X syndrome, an autism spectrum disorder, and a combination thereof.
